Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

Conditions

• Chronic Plaque Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Placebo — DRUG
  Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
• secukinumab (AIN457) — DRUG
  secukinumab (AIN457) 150mg or 300mg subcutaneous
• etanercept — DRUG
  etanercept 50mg subcutaneous

Study Details

This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.

Key Dates

Start date

Jun 30, 2011

Status verified

Mar 2019

Primary completion

Jul 31, 2013

Completion

Jul 31, 2013

Study Design

Enrollment

1,306 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: AIN457 150mg
  AIN457 150mg
• Experimental: AIN457 300mg
  AIN457 300mg
• Placebo Comparator: Placebo
  Placebo
• Active Comparator: Etanercept
  Etanercept
• Experimental: AIN457 150mg from Placebo
  Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase
• Experimental: AIN457 300mg from Placebo
  Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase

Primary Outcome Measure

Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . [ Time Frame: 12 wks ]

Locations (13)

Find similar trials in Birmingham, AL